Aethlon Medical Inc (AEMD)

AEMD.............................................................a/h

Anyone make the conference call yesterday? Replay available.

AEMD.............................https://stockcharts.com/h-sc/ui?s=AEMD&p=W&b=5&g=0&id=p86431144783

https://www.fiercepharma.com/pharma/fdas-acting-cder-head-corrigan-curay-heads-exit-amid-period-heavy-turnover-reports?oly_enc_id=4924G0643390I0A

New era coming together so nice.
i bot some more for the heck of it before Thursday.

AEMD reports Thursday 6/26

Breaking: RFK Jr. Removes All Members of CDC Vaccine Advisory Committee

HHS Secretary Robert F. Kennedy Jr. announced late today that he is retiring all 17 members of the CDC vaccine advisory committee. “A clean sweep is needed to re-establish public confidence in vaccine science,” Kennedy wrote in an op-ed published today in The Wall Street Journal.
by Brenda Baletti, Ph.D.Suzanne Burdick, Ph.D.
June 9, 2025

AEMD.........................https://stockcharts.com/h-sc/ui?s=AEMD&p=W&b=5&g=0&id=p86431144783

Hemopurifier one patient treated .66 +'7%

now WE starting to the moon

imho

here wow and boooooom https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175615997

quiet board :)

$AEMD Offering out https://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/95164825/form-1-a-offering-statement-regulation-a

I believe anything with Bird flu virus has a direction connection to AEMD
Read this from Friday...
https://ih.advfn.com/stock-market/NASDAQ/aethlon-medical-AEMD/stock-news/95139713/aethlon-medical-provides-update-on-the-ability-of

https://stocktwits.com/symbol/AEMD

I like NVNI and QNCCF (very much)...not interested in OWUV enough of 00's stocks. More scams than anything else. Very limited to what I like among those. LOL

Do you really think (?) AEMD can explode on Monday, because what does AEMD have to do with this article? Really? I don't understand the connection... somehow I'm confused... unfortunately, or why isn't AEMD already on Friday? It explodes after hours, what a pity, and let's earn a few dollars on Monday ($NVNI, $QNCCF, $OWUV

This will explode Monday
https://apnews.com/article/bird-flu-h5n1-spread-people-e5edab844b409b8ba21feaecb10156d0

looks good , should moving up now

moving up

aemd..........................https://stockcharts.com/h-sc/ui?s=aemd&p=W&b=5&g=0&id=p86431144783

Is there really 14 mill OS here?

Volume was 2nd highest of the year the other day I believe... What do peeps think?

BIRD FLU NEWS IS GOOD What if I told you $AEMD is a Bird Flu, MPOX and Marburg play?— TheStockDon (@TheStockDon) December 18, 2024

@AEMD pic.twitter.com/oxerG0WS5H— THE FINAL COUNTDOWN (@THIS_TIME_X) December 20, 2024

Not bad .62 +'42% can fall
Quick although 

18 Dec 2024
0.6606
0.2949
80.64%
0.3717
0.89
0.3491
46,335,477

amed...................https://stockcharts.com/h-sc/ui?s=aemd&p=W&b=5&g=0&id=p86431144783

AEMD....................................https://stockcharts.com/h-sc/ui?s=AEMD&p=W&b=5&g=0&id=p86431144783

https://www.stocktitan.net/news/AEMD/immunotherapy-clinical-trials-a-new-approach-to-treating-yvk6j9ox84ok.html

we need break .50
imo

nice News Yesterday

AEMD..................................https://stockcharts.com/h-sc/ui?s=AEMD&p=W&b=5&g=0&id=p86431144783

AEMD...BEASTING.....AND DUMPING

AEMD new 52 week low

I see...ty...🥳

AEMD new 52 week low

AEMD...45s clearing here...https://schrts.co/FxusTbFs ...Trying to bounce off the bottom band...🥳

AEMD… Daily Bullish Engulfing candle…
https://schrts.co/GWShQnbE

https://www.uspostnews.com/2024/06/24/aethlon-medical-inc-aemd-stock-analysis-a-simple-moving-average-approach/

BOOOM!!!
H.C. Wainwright cuts target price to $7 from $10 * Affirm Holdings : Goldman Sachs assumes coverage with buy vs neutral rating; PT $42 vs $21 *

https://finance.yahoo.com/news/aemd-ethics-committee-approval-safety-125800095.html

If bird flu accelerates this is the best thing going for AEMD!!! NO BRAINER!!!

Additionally, in vitro, the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes."

New Human Cases of Avian Flu Anticipated

Allison Shelley
June 19, 2024
25
253

With avian influenza spreading quickly around the globe, the virus has more opportunities to mutate and cause problems for people. By some calculations, H5N1 bird flu is still at least two mutations away from widespread human infections, but experts warn that new flu symptoms in individuals at high risk are likely to start turning up in health systems this summer.

"There is a broad range of symptoms to be watching for," said Vivien Dugan, PhD, director of the influenza division at the US Centers for Disease Control and Prevention (CDC). "Some of this will not be obvious or at the forefront of our minds."

Dugan is leading the team of CDC scientists that is working with partners from the US Department of Agriculture, the US Food and Drug Administration (FDA), and state and local health departments to track and respond to the H5N1 bird flu outbreak currently sweeping through the US.


Since 2022, avian influenza A viruses have been detected in more than 9300 wild birds in 50 states and territories and in commercial and backyard flocks.

"It's a bad situation," said Florian Krammer, PhD, professor of vaccinology at the Icahn School of Medicine at Mount Sinai in New York. "Globally, we've seen tons of exposure in cities around the world and even in the birds here in New York City where I am."

Birds shed the virus in their saliva, mucous, and feces, so people or other animals with close, unprotected contact with infected birds or their contaminated environments can be infected.


And for the first time in March 2024, H5N1 bird flu was reported in dairy cows. The US Department of Agriculture said that at last count 101 dairy herds in 12 states had been infected, with several cases also found in dairy workers.

From Birds to Cattle and Farm Workers
The National Veterinary Services Laboratories confirmed the infections were highly pathogenic avian influenza H5N1 clade 2.3.4.4b of Eurasian lineage. Also known as the goose, Guangdong clade from China, phylogenetic analysis and epidemiology suggests a single introduction into cows followed by onward transmission.

"I was surprised when H5 was introduced to dairy cattle in this way," Dugan said during an interview. "Influenza viruses are always surprising us and it reminds me to stay humble and keep an open mind when dealing with them."

I agree atleast they have PRs and not like HOLO who everyone thinks is going to $100. lol

Back to at least 2$ again

How is AEMD at .60 WHEN THEY LOWERED IT FROM $10 to $7? SMH

AEMD 10Q expected Thursday 6/27

$AEMD short interest increased to 69% from 60% last week. Also showing No Shares left to borrow

https://www.newsfilecorp.com/release/213511/Whats-Next-in-Treatments-for-Cancer-Patients-with-Solid-Tumors

What's Next in Treatments for Cancer Patients with Solid Tumors?


June 20, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (Nasdaq:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Research released this year predicts, "The solid tumor therapeutics market size will grow from USD 222.71 Billion in 2023 to USD 885.44 Billion in 10 years. Increasing investments of pharmaceutical companies in Research & Development will drive the solid tumor therapeutics market's growth. North America emerged as the largest market for the global Solid Tumor Therapeutics market, accounting for 44% of the total market share globally."

AEMD .675… Daily psar flipped to the Bullish Buy side with volume: Bullish Harami and Inverted hammer candlestick, in one, with, upper gaps to fill in the dollar range to boot…
https://schrts.co/QDZNIdNs

The Hunt for Virus Treatments Continues Post Covid-19
Newsfile - Fri Jun 7, 7:16AM CDT Contributor Content

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 7, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Read the full article on Investorideas.com
https://www.investorideas.com/News/2024/biotech/06070Virus-Treatments-Post-Covid-19.asp

The threat of viruses is back in the news with multiple news sources, including the Guardian reporting, "The World Health Organization (WHO) has said a man's death in Mexico was caused by a strain of bird flu called H5N2 that has never before been found in a human."

The WHO said Wednesday it wasn't clear how the person became infected. "Although the source of exposure to the virus in this case is currently unknown, A (H5N2) viruses have been reported in poultry in Mexico," it said in a statement.

Continued: "Scientists are on alert for changes in the virus that could signal that bird flu is adapting to spread more easily among humans.

Continued: "But the UN agency said Wednesday said the current risk of the bird flu virus to the general population in Mexico is low."

With global populations and economies still feeling the impact of Covid-19, any virus threat is going to make headlines.

As viruses make headlines, companies are seeking solutions and not all are focused on vaccine development.

Aethlon Medical, Inc. (NASDAQ: AEMD) just recently announced an update on its technology for cancer treatment on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

The Aethlon Hemopurifier® technology is designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a "Breakthrough Device" for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.

As reported previously, separate from its current focus on cancer treatment, Aethlon has investigated the potential for the use of the Hemopurifier® in viral diseases.

According to their SEC filing, "We also believe the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola."

"Additionally, in vitro, the Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research institutes."

Recently, Zacks reported that "Vaccine Stocks Rise on Growing Threat of Bird Flu Infections."

"Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna and Pfizer to set up a possible vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans."

Continued: "These reports came to light after the discovery of two cases of H5N1 virus in dairy farm workers in Texas and Michigan this year. Both these workers experienced symptoms in the eye after coming into contact with dairy cows infected with the H5N1 virus."

But the treatment of viral diseases has other options including immunotherapy.

ImmunityBio, a clinical-stage immunotherapy company, announced earlier this year the publication of preclinical data in the online issue of Science, First Release indicating that combination therapy with N-803, an IL-15 superagonist, and broadly neutralizing antibodies may potentially enable the immune system to manage human immunodeficiency virus (HIV) without the need for antiretroviral treatment.

NEWSSSS!

June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on June, 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027. The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital, located in Adelaide, Australia.

Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

"The approval from the Human Research Ethics Committee at Central Adelaide Local Health Network marks a significant milestone for Aethlon, as they deemed that our clinical study meets the requirements of the Australia's National Statement on Ethical Conduct in Human Research," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "We look forward to working closely with Prof. Brown and his staff, and with our Contract Research Organizations, NAMSA and ReSQ Clinical Research. The next steps include submission to the Therapeutic Goods Administration, the national health regulatory agency of Australia, obtaining approval from the CALHN Research Governance Committee, and conducting a site initiation visit to facilitate patient enrollment. Following this Ethics Board approval, we plan to submit to the Ethics Committees at two additional sites in Australia and one in India."

The primary endpoint of the approximate 18-patient, safety, feasibility and dose-finding trial is safety. The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.